Carboplatin, vinblastine and mitomycin-C in the treatment of non-small cell bronchogenic carcinoma.
Thirty patients with advanced non-small cell lung carcinoma were treated with carboplatin, vinblastine and mitomycin-C. Objective tumor regression was noted in 6 patients. Toxicity of this combination was moderate.
Athanassiades
P
P
Department of Clinical Therapeutics, Medical School, Athens University, Alexandra Hospital, Greece.
Athanassiades
H
H
Psychogiou
E
E
Kokolakis
N
N
Giannioti
E
E
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D014747:Vinblastine / Q000008:administration & dosage
D016685:Mitomycin; D014747:Vinblastine; D016190:Carboplatin